Fluoroquinolone resistance and clinical characteristics of acute bacterial prostatitis in Japan: A multicenter study by the Japanese Research Group for Urinary Tract Infection.

acute bacterial prostatitis antimicrobial treatment fluoroquinolone resistance inpatient transrectal prostate biopsy

Journal

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
ISSN: 1437-7780
Titre abrégé: J Infect Chemother
Pays: Netherlands
ID NLM: 9608375

Informations de publication

Date de publication:
14 Aug 2024
Historique:
received: 24 06 2024
revised: 09 08 2024
accepted: 13 08 2024
medline: 17 8 2024
pubmed: 17 8 2024
entrez: 16 8 2024
Statut: aheadofprint

Résumé

This multicenter study aimed to analyze the risk factors for fluoroquinolone (FQ) resistance and to clarify the clinical characteristics of acute bacterial prostatitis (ABP) in Japan. A total of 124 patients clinically diagnosed with ABP at 13 medical institutions participating in the Japanese Research Group for Urinary Tract Infection between January and December 2017 were retrospectively reviewed. Of the 124 patients included in this study, 37 were outpatients, and 87 were inpatients. The main underlying medical conditions before the onset of ABP were severe dysuria, urinary retention, transurethral manipulation, indwelling urinary catheter, and transrectal prostate biopsy (TRBx). The main symptoms were fever (≥ 37.5°C), prostate tenderness, dysuria, micturition pain, urinary retention, and macrohematuria. Bacteremia was observed in 14 patients. Prostatic abscess was observed in three patients. Escherichia coli was the predominant organism, accounting for 48% (51/106). FQ-resistant E. coli was detected in 33% (17/51), and extended-spectrum beta-lactamases-producing E. coli in 12% (6/51). TRBx (odds ratio [OR] = 48.60, 95% confidence interval [CI]: 5.49-430.00, p < 0.001) and inpatient status (OR = 29.00, 95% CI: 1.95-430.00, p = 0.014) were risk factors for the detection of FQ-resistant bacteria. The detection rate of FQ-resistant bacteria was significantly higher with TRBx ABP and inpatient status. These findings have important implications for the management of ABP and antimicrobial treatment, especially for TRBx ABP, which should be considered a separate category.

Identifiants

pubmed: 39151550
pii: S1341-321X(24)00221-6
doi: 10.1016/j.jiac.2024.08.012
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no conflicts of interest.

Auteurs

Masahiro Matsumoto (M)

Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan. Electronic address: mmatsumoto@med.uoeh-u.ac.jp.

Ryoichi Hamasuna (R)

Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan; Department of the Urology, Federation of National Public Service Personnel Mutual Aid Associations, Shin-Kokura Hospital, Kitakyushu, JRGU, Japan.

Koichiro Wada (K)

Department of Urology, Shimane University Faculty of Medicine, Shimane, JRGU, Japan.

Takuya Sadahira (T)

Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, JRGU, Japan.

Katsumi Shigemura (K)

Department of Urology, Teikyo University School of Medicine, Tokyo, JRGU, Japan.

Maeda Kouki (M)

Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Hyogo, JRGU, Japan.

Yoshiki Hiyama (Y)

Department of Urology, Sapporo Medical University School of Medicine, Hokkaido, JRGU, Japan.

Yoshikazu Togo (Y)

Department of Urology, Kawanishi City Medical Center, Hyogo, JRGU, Japan.

Seiji Nagasawa (S)

Department of Urology, Kawanishi City Medical Center, Hyogo, JRGU, Japan.

Kazuaki Yamanaka (K)

Department of Urology, Shiga University of Medical Science, Shiga, JRGU, Japan.

Kazuyoshi Shigehara (K)

Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Ishikawa, JRGU, Japan.

Kanao Kobayashi (K)

Department of Urology, Chugoku Rosai Hospital, Hiroshima, JRGU, Japan.

Haruki Tsuchiya (H)

Department of Urology, Hitachi, Ltd. Hitachinaka General Hospital, Ibaraki, JRGU, Japan.

Jun Miyazaki (J)

Department of Urology, International University of Health and Welfare Narita Hospital, Chiba, JRGU, Japan.

Tohru Nakagawa (T)

Department of Urology, Teikyo University School of Medicine, Tokyo, JRGU, Japan.

Kiyohito Ishikawa (K)

Department of Quality and Safety in Healthcare, Division of Infection Control and Prevention, Fujita Health University Hospital, Aichi, JRGU, Japan.

Satoshi Takahashi (S)

Department of Infection Control and Laboratory Medicine, Sapporo Medical University School of Medicine, Hokkaido, JRGU, Japan.

Naohiro Fujimoto (N)

Department of Urology, University of Occupational and Environmental Health, Kitakyushu, The Japanese Research Group for Urinary Tract Infection (JRGU), Japan.

Shingo Yamamoto (S)

Department of Urology, Hyogo College of Medicine, Hyogo, JRGU, Japan.

Classifications MeSH